LILLY-I4T-IE-JVBE

Study Sponsor: Lilly

Study Title

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

Medicine or Vaccine (generic name)

Ramucirumab

Sponsor Identification Number

I4T-IE-JVBE

Trial Registry Identification Number(#'s)

NCT01170663

Medical Condition

Gastric Cancer

Phase

Phase 3

Link to study details on the Lilly Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT01170663?term=I4T-IE-JVBE&rank=1

Link to study details on EudraCT (if available)

Not available

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

November 2015